Recently Diagnosed Atrial Fibrillation in Patients with Acute Coronary Syndrome: Results of the FORCE-ACS Registry

Atrial fibrillation (AF) is a common condition in patients with acute coronary syndrome (ACS). About 10% of patients undergoing percutaneous coronary intervention (PCI) have AF, while 25%-35% of patients with AF have coronary artery disease. The joint management of both conditions poses a significant challenge, as the combination of oral anticoagulation (OAC) and dual antiplatelet therapy (DAPT), known as triple therapy, is associated with a high risk of bleeding complications.

There is limited information regarding the prognosis and optimal antithrombotic treatment in patients with newly diagnosed AF during ACS. Observational studies have shown that these patients with AF and ACS often receive inadequate treatment, as OAC is not always prescribed. Therefore, it is crucial to determine whether newly diagnosed AF entails a higher risk of thromboembolic events.

The aim of this multicenter, prospective study was to assess the incidence of de novo AF in patients with ACS, compare clinical outcomes between those without AF, subjects with de novo AF, and those with known AF, and analyze antithrombotic treatment in relation to major adverse cardiovascular events (MACE), with particular attention to stroke.

The primary endpoint (PEP) was the rate for MACE, defined as all-cause mortality, acute myocardial infarction (AMI), and ischemic stroke. The secondary endpoint (SEP) included ischemic stroke and bleeding complications.

Read also: ESC 2024 | REC-CAGEREE I Trial: Drug Coated Balloon with Bailout Stenting vs. Intended DES for de Novo Lesion Treatment.

The study included 4433 patients with ACS, of whom 81.2% had no AF, 9.9% had newly diagnosed AF, and 9% had known AF. Patients with newly diagnosed AF and known AF were older and had more comorbidities compared with those without AF (mean age 71, 74, and 65 years, respectively; p < 0.001). The rate of OAC treatment at discharge was 53.4% in patients with de novo AF and 89.2% in patients with known AF.

De novo AF was independently associated with an increased rate of MACE, whereas known AF did not evidence this association (hazard ratio [HR] 1.52; 95% confidence interval [CI] 1.19-1.90 vs. HR 0.93; 95% CI 0.70-1.23). In patients diagnosed with ACS and newly onset AF, AF episodes lasting longer than 24 hours were associated with a higher risk of MACE compared with episodes lasting less than 24 hours (HR 1.99; 95% CI: 1.36-2.93).

Conclusion

In patients with ACS, newly diagnosed AF was associated with worse outcomes in terms of MACE and ischemic stroke. In those with newly diagnosed AF, AF episodes lasting longer than 24 hours were linked to worse outcomes compared with shorter episodes. Additionally, only half of the patients with de novo AF were discharged with OAC, in contrast to more than 90% of patients with known AF.

Original Title: Outcomes of newly diagnosed atrial fibrillation in patients with acute coronary syndromes.

Reference: Willem Lambertus (Wilbert) Bor, MD et al EuroIntervention 2024;20:996-1007.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...